Gruson D, Buglioni A, Burnett J C
Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium; Department of Laboratory Medicine, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA.
Clin Chim Acta. 2014 Jun 10;433:290-6. doi: 10.1016/j.cca.2014.03.029. Epub 2014 Apr 1.
Biomarkers play an important role for the diagnosis and prognosis of heart failure (HF), a disease with high morbidity and mortality as well as a huge impact on healthcare budgets. Parathyroid hormone (PTH) is a major systemic calcium-regulating hormone and an important regulator of bone and mineral homeostasis. PTH testing is important for differential diagnosis of calcemia related disorders and for the management of patients with chronic kidney disease. As secondary hyperparathyroidism has been evidenced in HF patients, PTH testing might be relevant in HF patients for risk stratification and more personalized selection of treatment.
生物标志物在心力衰竭（HF）的诊断和预后中起着重要作用，心力衰竭是一种发病率和死亡率高且对医疗保健预算有巨大影响的疾病。甲状旁腺激素（PTH）是一种主要的全身钙调节激素，也是骨和矿物质稳态的重要调节因子。PTH检测对于与血钙相关疾病的鉴别诊断以及慢性肾病患者的管理很重要。由于已证实HF患者存在继发性甲状旁腺功能亢进，PTH检测可能与HF患者的风险分层及更个性化的治疗选择相关。
Zotero 插件